A Maharashtra FDA survey has placed the pricing of basic medical devices at the centre of a wider healthcare governance question: when a patient is hospitalised and cannot choose or negotiate over essential consumables, who protects them from excessive charges? The agency’s findings, submitted to the Department of Pharmaceuticals, show substantial differences between purchase prices and declared maximum retail prices for intravenous sets, syringes, nebulisers, oxygen masks and other products.
The figures cited in the survey are striking. An intravenous set purchased for Rs 11.05 carried a declared MRP of Rs 325, while an infusion set bought for Rs 11 had an MRP of Rs 201. A 10-ml syringe purchased for Rs 6.75 had a declared MRP of Rs 57.20. A hypodermic needle bought for Rs 1 carried an MRP of Rs 3.30.
The same pattern appeared in nebuliser products. The survey found that a Nebplus product bought for Rs 40 carried an MRP of Rs 715. An adult nebuliser mask kit purchased for Rs 45 had a declared MRP of Rs 652. These are survey findings reported by the Maharashtra State Price Monitoring Resource Unit under the Maharashtra FDA and cited by news agency PTI. They do not, by themselves, establish what hospitals ultimately charged patients or whether every listed product was sold at its declared MRP. They do, however, identify a significant gap requiring regulatory examination.
That distinction matters because the pricing system for a hospital product is not the same as an ordinary retail transaction. A consumer buying a household item can compare brands, delay a purchase or move to another shop. A patient receiving inpatient treatment generally cannot do so when a doctor or hospital requires a particular consumable during a procedure or course of treatment. The purchasing decision may be made by the institution, while the financial burden is passed to the patient or insurer.
Maharashtra FDA commissioner Tukaram Mundhe described this as an information asymmetry problem. “Healthcare is not a conventional marketplace. A hospitalised patient needing an essential medical device cannot reasonably compare prices or negotiate costs,” he told PTI. He said this vulnerability could increase out-of-pocket expenditure and argued that information asymmetry should not become an opportunity for excessive pricing.
The survey therefore raises a question beyond the MRP of individual products: how should pricing oversight work when medical devices move through several layers of manufacture, distribution, hospital procurement and patient billing? A declared MRP is only one part of that chain. The available report does not provide a full breakdown of manufacturer cost, distributor margin, hospital procurement terms, taxes, wastage, storage or the final amount charged to patients. Without that information, the precise source of the gap cannot be determined from the survey alone.
What the findings do show is that the existing framework may not give regulators enough visibility over essential devices. The FDA has referred to regulatory gaps in the current pricing system and sought a structured response rather than action limited to individual complaints. Its recommendations include regulation of trade margins, systematic price monitoring and guidelines on the permissible differential between procurement prices and declared MRPs.
The agency has asked the Department of Pharmaceuticals to examine the findings in consultation with the National Pharmaceutical Pricing Authority and other concerned authorities. It has also proposed stronger price-monitoring mechanisms at both state and national levels. The report was submitted as an evidence-based policy input, including a request to examine whether the listed devices could be brought within an appropriate price-regulation mechanism, including possible inclusion in the relevant framework of the Drugs (Prices Control) Order, 2013.
This institutional route is important. The Maharashtra FDA can identify market conditions and report concerns, but a broader pricing framework would require coordination between the state regulator, the Department of Pharmaceuticals and the National Pharmaceutical Pricing Authority. Decisions on price control, trade margins or permissible differentials would also need to account for product classification, supply chains and differences between essential and non-essential devices.
The issue also exposes the limits of treating medical devices as a single category. An IV set, syringe, needle and nebuliser product may all be used in hospitals, but their manufacturing processes, specifications, packaging and distribution arrangements can differ. A workable oversight system would therefore need product-level information rather than only broad declarations. The FDA’s request for structured monitoring points towards that requirement, although the supplied report does not specify what form a future monitoring system would take.
For patients, the practical concern is not simply the price printed on packaging. It is the lack of visibility at the point of care. Hospitalised patients and their families may receive a bill containing multiple consumables without knowing the procurement price, available alternatives or the margin applied at each stage. The FDA’s report specifically notes that patients undergoing inpatient treatment have limited ability to compare prices or negotiate, linking the pricing question directly to healthcare access and household expenditure.
The figures also show why price transparency and price regulation cannot be treated as identical interventions. Publishing procurement and billing information could make differences easier to identify, while margin controls or price ceilings could directly limit the amount charged. The FDA has sought examination of both issues, but the report does not announce any new national ceiling or immediate change in hospital billing rules.
That limitation is central to understanding what has happened. Maharashtra has flagged a problem and requested that the Centre examine it; the Centre has not, on the evidence supplied, announced a final policy decision. The survey is therefore an opening document in a regulatory process, not a completed price-control regime. Its impact will depend on whether the Department of Pharmaceuticals and the NPPA validate the findings, define the relevant device categories and decide what form of oversight is legally and administratively feasible.
The larger urban question is how public healthcare systems protect citizens in settings where choice is structurally unequal. Hospitals are essential urban institutions, but patients inside them do not operate as ordinary consumers. Their ability to question prices is constrained by urgency, medical dependence and incomplete information. When essential devices are billed through institutional systems, accountability must extend beyond the point of sale to procurement, inventory, disclosure and patient billing.
The Maharashtra FDA’s survey confirms that substantial procurement-to-MRP differences exist in the products it examined. It does not yet establish a national pattern, determine the final patient charge or settle whether every difference represents an unlawful or excessive margin. The next steps are the Department of Pharmaceuticals’ examination of the findings, consultation with the NPPA and other authorities, and any decision on price monitoring, trade-margin regulation or inclusion under the relevant price-control framework.
